| 商品名称 | Tecovirimat SIGA |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Poxviridae Infections;Cowpox;Monkeypox;Vaccinia;Smallpox |
| 通用名/非专利名称 | tecovirimat monohydrate |
| 活性成分 | tecovirimat |
| 产品号 | EMEA/H/C/005248 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | J05AX24 |
| 是否额外监管 | Yes |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | Yes |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2022/01/06 |
| 上市许可开发者/申请人/持有人 | SIGA Technologies Netherlands B.V. |
| 人用药物治疗学分组 | Antivirals for systemic use |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2021/11/11 |
| 欧盟委员会决定日期 | 2024/10/02 |
| 修订号 | 5 |
| 治疗适应症 | Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg: Smallpox Monkeypox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1). Tecovirimat SIGA should be used in accordance with official recommendations. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2021/11/10 |
| 最后更新日期 | 2025/11/10 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/tecovirimat-siga-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga |